CN103974955B - 嘧啶并-哒嗪酮化合物及其用途 - Google Patents
嘧啶并-哒嗪酮化合物及其用途 Download PDFInfo
- Publication number
- CN103974955B CN103974955B CN201280051788.8A CN201280051788A CN103974955B CN 103974955 B CN103974955 B CN 103974955B CN 201280051788 A CN201280051788 A CN 201280051788A CN 103974955 B CN103974955 B CN 103974955B
- Authority
- CN
- China
- Prior art keywords
- bases
- amino
- pyridazine
- phenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **N1C(*)C(*)*C(*)C1* Chemical compound **N1C(*)C(*)*C(*)C1* 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
Description
Claims (43)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810492306.1A CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526525P | 2011-08-23 | 2011-08-23 | |
US61/526,525 | 2011-08-23 | ||
PCT/US2012/051980 WO2013028818A1 (en) | 2011-08-23 | 2012-08-23 | Pyrimido- pyridazinone compounds and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810492306.1A Division CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103974955A CN103974955A (zh) | 2014-08-06 |
CN103974955B true CN103974955B (zh) | 2018-06-19 |
Family
ID=46829884
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810492306.1A Active CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
CN201280051788.8A Active CN103974955B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810492306.1A Active CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Country Status (13)
Country | Link |
---|---|
US (5) | US8729079B2 (zh) |
EP (4) | EP3392252B1 (zh) |
JP (1) | JP5993010B2 (zh) |
CN (2) | CN108707151B (zh) |
BR (1) | BR112014003981A2 (zh) |
CA (1) | CA2846187A1 (zh) |
DK (2) | DK3392252T3 (zh) |
ES (1) | ES2690971T3 (zh) |
FI (1) | FI3392252T3 (zh) |
IL (1) | IL231082A (zh) |
MX (1) | MX361458B (zh) |
PL (1) | PL2748166T3 (zh) |
WO (1) | WO2013028818A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707151A (zh) * | 2011-08-23 | 2018-10-26 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
EP3615032A4 (en) * | 2017-04-28 | 2020-12-23 | Asana BioSciences, LLC | FORMULATIONS, PROCEDURES, KITS AND DOSING FORMS FOR TREATMENT OF ATOPIC DERMATITIS AND IMPROVED STABILITY OF AN ACTIVE INGREDIENT |
CN111961035B (zh) * | 2019-05-20 | 2022-11-01 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
CN114174298B (zh) * | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
CN113583026A (zh) * | 2020-04-30 | 2021-11-02 | 杭州英创医药科技有限公司 | 一类含有稠合三环结构的化合物 |
TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
WO2023122662A1 (en) * | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
WO2023164024A1 (en) | 2022-02-23 | 2023-08-31 | Teva Pharmaceuticals International Gmbh | Solid state forms of gusacitinib |
WO2023192989A2 (en) * | 2022-04-01 | 2023-10-05 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE756508A (fr) * | 1969-09-24 | 1971-03-01 | Takeda Chemical Industries Ltd | Derives de pyrimidopyridazine |
CA1004223A (en) * | 1972-05-12 | 1977-01-25 | Theodor Denzel | Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters |
JPS4948695U (zh) | 1972-07-29 | 1974-04-27 | ||
JPS50101387A (zh) * | 1974-01-16 | 1975-08-11 | ||
CA1052046A (en) | 1974-01-21 | 1979-04-03 | American Cyanamid Company | Unsymmetrically substituted 1,4-dioxane-2,5-diones |
US5369086A (en) | 1993-04-28 | 1994-11-29 | Zeneca Limited | N-benzotriazoles |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
JPH0948695A (ja) | 1995-08-02 | 1997-02-18 | Toshiba Ceramics Co Ltd | シリコン単結晶の製造方法 |
EP1060179A1 (en) | 1998-02-25 | 2000-12-20 | PHARMACIA & UPJOHN COMPANY | Substituted aminomethyl isoxazoline derivatives useful as antimicrobials |
HU230394B1 (hu) | 1998-11-10 | 2016-04-28 | Janssen Pharmaceutica N.V. | HIV-vírus szaporodását gátló pirimidin-származékok |
BR0113987A (pt) * | 2000-09-22 | 2003-08-12 | Akzo Nobel Nv | Composto heteromático bicìclico, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de derivados heteroaromáticos bicìclicos ou de um sal ou solvato farmaceuticamente aceitável dos mesmos |
ES2301633T3 (es) | 2001-04-30 | 2008-07-01 | Glaxo Group Limited | Pirimidinas condensadas como antagonistas del factor de liberacion de corticotropina (crf). |
WO2003075828A2 (en) | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
DK1534286T3 (da) | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2533377C (en) | 2003-07-30 | 2012-11-27 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
BRPI0516746A (pt) | 2004-09-30 | 2008-09-23 | Tibotec Pharm Ltd | 5-heterociclil pirimidinas para inibição de hiv |
SI1830869T1 (sl) | 2004-12-24 | 2013-12-31 | Spinifex Pharmaceuticals Pty Ltd | Postopek zdravljenja ali profilakse |
AU2006226322B2 (en) | 2005-03-25 | 2012-03-29 | Tibotec Pharmaceuticals Ltd. | Heterobicylic inhibitors of HCV |
CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
KR20080000584A (ko) | 2005-04-29 | 2008-01-02 | 얀센 파마슈티카 엔.브이. | 카나비노이드 수용체 길항제로서의 벤조트리아졸 유도체 |
EP1970373A1 (en) * | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
KR101449436B1 (ko) * | 2006-12-28 | 2014-10-14 | 애브비 인코포레이티드 | 폴리(adp-리보스)폴리머라제 억제제 |
NZ579480A (en) | 2007-03-14 | 2012-03-30 | Exelixis Patent Co Llc | 2-Arylamino-quinazoline derivatives |
TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
TW201018693A (en) * | 2008-09-30 | 2010-05-16 | Astrazeneca Ab | Chemical compounds 496-1p |
AR073760A1 (es) | 2008-10-03 | 2010-12-01 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
MX2011004125A (es) | 2008-10-21 | 2011-05-19 | Metabolex Inc | Agonistas del receptor gpr120 de arilo y usos de los mismos. |
US8404677B2 (en) * | 2009-10-29 | 2013-03-26 | Genosco | Kinase inhibitors |
TW201130852A (en) * | 2009-12-23 | 2011-09-16 | Abbott Lab | Novel thienopyrrole compounds |
WO2012058671A1 (en) | 2010-10-31 | 2012-05-03 | Endo Pharmaceuticals Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
CN108707151B (zh) * | 2011-08-23 | 2022-06-03 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
WO2014022728A1 (en) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer |
AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
EP3615032A4 (en) * | 2017-04-28 | 2020-12-23 | Asana BioSciences, LLC | FORMULATIONS, PROCEDURES, KITS AND DOSING FORMS FOR TREATMENT OF ATOPIC DERMATITIS AND IMPROVED STABILITY OF AN ACTIVE INGREDIENT |
-
2012
- 2012-08-23 CN CN201810492306.1A patent/CN108707151B/zh active Active
- 2012-08-23 DK DK18175788.1T patent/DK3392252T3/da active
- 2012-08-23 MX MX2014002112A patent/MX361458B/es active IP Right Grant
- 2012-08-23 PL PL12756865T patent/PL2748166T3/pl unknown
- 2012-08-23 WO PCT/US2012/051980 patent/WO2013028818A1/en active Application Filing
- 2012-08-23 EP EP18175788.1A patent/EP3392252B1/en active Active
- 2012-08-23 EP EP12756865.7A patent/EP2748166B1/en active Active
- 2012-08-23 BR BR112014003981A patent/BR112014003981A2/pt not_active IP Right Cessation
- 2012-08-23 CN CN201280051788.8A patent/CN103974955B/zh active Active
- 2012-08-23 EP EP23201319.3A patent/EP4327886A2/en active Pending
- 2012-08-23 EP EP18182723.9A patent/EP3404029A3/en not_active Withdrawn
- 2012-08-23 US US13/592,511 patent/US8729079B2/en active Active
- 2012-08-23 JP JP2014527282A patent/JP5993010B2/ja active Active
- 2012-08-23 DK DK12756865.7T patent/DK2748166T3/en active
- 2012-08-23 ES ES12756865T patent/ES2690971T3/es active Active
- 2012-08-23 FI FIEP18175788.1T patent/FI3392252T3/fi active
- 2012-08-23 CA CA2846187A patent/CA2846187A1/en active Pending
-
2014
- 2014-02-23 IL IL231082A patent/IL231082A/en active IP Right Grant
- 2014-04-03 US US14/244,183 patent/US9382277B2/en active Active
-
2016
- 2016-04-25 US US15/137,950 patent/US10183944B2/en active Active
-
2018
- 2018-11-30 US US16/206,395 patent/US10647720B2/en active Active
-
2020
- 2020-02-25 US US16/800,111 patent/US20200190095A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707151A (zh) * | 2011-08-23 | 2018-10-26 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103974955B (zh) | 嘧啶并-哒嗪酮化合物及其用途 | |
ES2219670T3 (es) | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. | |
ES2299434T3 (es) | Inhibidores de kinasa utilizados como agentes terapeuticos. | |
KR101686685B1 (ko) | 피라졸로피리미딘 jak 억제제 화합물 및 방법 | |
DE69928414T2 (de) | 4-aminopyrrolopyrimidine als kinaseinhibitoren | |
ES2288694T3 (es) | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. | |
JP4707167B2 (ja) | キナーゼ阻害剤 | |
CN107889488A (zh) | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 | |
CN102858770A (zh) | 双环化合物及其作为c-SRC/JAK激酶双重抑制剂的用途 | |
US11306095B2 (en) | Use of pteridinone derivative serving as EGFR inhibitor | |
IL175572A (en) | Condensed heterocycles, jak selective kinase inhibitors and pharmaceutical compositions comprising them | |
JP2002526500A (ja) | プロテインキナーゼ阻害剤としてのピロロピリミジン | |
JP2004511470A (ja) | 蛋白キナーゼ阻害薬 | |
EP1870414A1 (en) | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency | |
WO2014104757A1 (ko) | Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물 | |
JP2006528685A (ja) | 新規化合物 | |
JP2008520749A (ja) | 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物 | |
CN105934248A (zh) | 取代的吡咯并吡啶和吡咯并吡嗪用于治疗癌症或炎性疾病 | |
TWI523856B (zh) | BCR-ABL kinase inhibitor and its application | |
US7071199B1 (en) | Kinase inhibitors as therapeutic agents | |
CN105968115B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
EP3749646B1 (en) | Heteroaryl compounds as kinase inhibitor | |
WO2023279938A1 (zh) | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 | |
DE60004340T2 (de) | Substituierte 1,4-dihydroindeno[1,2-c]pyrazole als inhibitoren von tyrosinkinase | |
CN106831812B (zh) | 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170323 Address after: New jersey, USA Applicant after: Asana BioSciences, LLC Address before: American Pennsylvania Applicant before: ENDO PHARMACEUTICALS INC. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220727 Address after: new jersey Patentee after: ABS development 1 Co.,Ltd. Address before: new jersey Patentee before: Asana BioSciences, LLC |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Liberty Biology Co.,Ltd. Address before: new jersey Patentee before: ABS development 1 Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |